M Tewar, MD

Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.

Mark Zimmerman, MD, discusses controversies related to categorizing severity and identifying optimal treatment of depression.